VectivBio is a spin out of Therachon, that will focus on conditions caused by well understood molecular alterations that can be targeted with transformational therapeutics. The lead product candidate is apraglutide, a next-generation, synthetic GLP-2 analog that has undergone extensive preclinical characterization and optimization as well as early clinical testing. It is being developed as a once-weekly, potential best-in-class therapeutic for the treatment of short bowel syndrome (SBS).